FES avid pulmonary adenocarcinoma and confounding ER+ breast carcinoma

Yousif M Abdelmoneim; Yanyan Lou; Pooja Advani; Andras Khoor; Akash Sharma; Ephraim E Parent

doi:10.1016/j.radcr.2024.10.114

FES avid pulmonary adenocarcinoma and confounding ER+ breast carcinoma

Radiol Case Rep. 2024 Nov 14;20(1):801-804. doi: 10.1016/j.radcr.2024.10.114. eCollection 2025 Jan.

Authors

Yousif M Abdelmoneim¹, Yanyan Lou¹, Pooja Advani¹, Andras Khoor², Akash Sharma³, Ephraim E Parent³

Affiliations

¹ Department of Oncology, Mayo Clinic Florida, FL, 32224, USA.
² Department of Pathology, Mayo Clinic Florida, FL, 32224, USA.
³ Department of Radiology, Mayo Clinic Florida, FL, 32224, USA.

Abstract

Breast carcinomas are well known for expression of estrogen receptor (ER) however there are other malignancies that are also express ER, possibly confounding the diagnostic interpretation of 16α-[¹⁸F]fluoro-17β-estradiol (FES; Cerianna GE HealthCare) in patients with both ER+ breast carcinomas and other malignancies. We present a case of a woman with prior history of both ER+ breast carcinoma and pulmonary adenocarcinoma with subsequent identification of an FES pulmonary nodule that was proven on histopathology to be consistent with an ER expressing pulmonary adenocarcinoma metastasis.

Keywords: Breast carcinoma; Estrogen receptor; FES; Pulmonary adenocarcinoma.

Publication types

Case Reports